As many as 1 in 7 Americans (more than 35 million people) have chronic kidney disease (CKD), especially those with diabetes and hypertension.  About 90% of them don’t feel ill and are not aware that they have CKD, according to the U.S. Centers for Disease Control and Prevention.  Early stages of CKD may go unnoticed unless uncovered during routine healthcare and screening that includes a test for serum creatinine and a test for protein in urine.  Left untreated or undertreated, CKD can be progressive, leading to end stage renal disease (ESRD) and kidney failure that requires frequent dialysis treatments or a kidney transplant.  Without these treatments, ESRD patients die. [Link: https://usrds-adr.niddk.nih.gov/2025]

Currently,  approximately 517,000 ESRD patients are on dialysis and 317,000 are living with transplants, totaling over 830,000 patients when combined (https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/1-ckd-in-the-general-population) Even with dialysis therapy or a kidney transplant, patients and their families endure complications and lifestyle disruptions associated with kidney failure management.  (https://www.cdc.gov/kidney-disease/about/index.html).(https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease)

Managing ESRD is expensive. It is one of only a few diseases covered primarily by Medicare (not private insurance) – regardless of the age of the patient. The Center of Medicare and Medicaid Services reports that CKD and ESRD account for over 25% of total Medicare Fee-for-Service (FFS) spending (more than $130 billion annually).  Patients with these conditions are only a small fraction (1.2%) of the total population receiving Medicare benefits (67 million people) (https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd). Since its’ founding in 2015, Rametrix Technologies Inc. (formerly Dialysensors LLC) has been heavily focused on developing and validating novel technologies to improve detection, management, and outcomes for CKD and ESRD – as demonstrated in numerous peer-reviewed publications.  With the evolution of Rametrix® Urine Molecular Fingerprinting™ (UMF) technology, application of UMF to improving organ transplantation, development of deployable point-of-care (POC) UMF analyzers, and ‘engineering lab’ prototyping of the PHD -Precision Hemodialysis System, RTI is ready to meet and overcome the CKD/ESRD national crisis.